Core Viewpoint - Suzhou New District High-tech Industry Co., Ltd. plans to sell 47% equity of Suzhou Medical Device Industry Development Group Co., Ltd. to Suzhou High-tech Zone State-owned Capital Holding Group Co., Ltd. for a transaction price of 604.44 million yuan, which will result in the company no longer consolidating the medical device company in its financial statements [2][4][18]. Transaction Overview - The transaction involves the sale of 47% equity of the medical device company at a price of 604.44 million yuan, reducing the company's holding from 51.37% to 4.37% [4][18]. - The board of directors approved the sale with unanimous support during the meeting held on November 25, 2025 [5][46]. - The transaction requires approval from the state-owned assets supervision and administration department [5]. Financial Information - The medical device company reported a revenue of 151.55 million yuan and a net loss of 81.81 million yuan for the year 2024 [9]. - The equity value of the medical device company was assessed at 1.286 billion yuan, with a book value of 1.139 billion yuan, indicating an appreciation of 147.29 million yuan (12.93%) [14][15]. Impact on the Company - The sale is expected to reduce the impact on the company's financial statements and enhance overall profitability, aligning with the interests of the company and its shareholders [18]. - The company will continue to manage existing investment funds and projects in the medical device sector post-transaction, maintaining a focus on high-quality enterprises in the industry [18].

Core Viewpoint - Suzhou Gaoxin plans to sell a 47% stake in Suzhou Medical Device Industry Development Group for 604 million yuan, aiming to reduce the impact of the medical device company's underperformance on its financial statements [1][2]. Group 1: Transaction Details - The transaction price of 604 million yuan is based on an asset valuation report, reflecting a 12.93% premium over the book value of the stake [2]. - The payment will be made in installments, with 51% due by January 7, 2026, and the remaining 49% by March 31, 2026 [2]. - Suzhou Gaoxin's cost basis for the stake was 535 million yuan, indicating a transaction premium [2]. Group 2: Company Performance - Suzhou Medical Device Industry Development Group reported a revenue of 152 million yuan for 2024 and a net loss of approximately 81.81 million yuan [1]. - For the first three quarters of 2025, the company generated 140 million yuan in revenue with a net loss of about 101 million yuan [1]. Group 3: Strategic Implications - The sale is expected to enhance Suzhou Gaoxin's overall profitability by reducing the negative impact of the medical device company's performance on its financials [3]. - The company will continue to manage existing funds and projects while focusing on quality enterprises in the medical device sector and promoting green low-carbon industrial park operations [3].